Blinatumomab: beyond clinical trials
(2017) Belgian Journal of Hematology — Vol. 8, n° 3, p. 107-112 (2017)
Files
GrauxCBJH2017.pdf
Restricted Access - Adobe PDF
- 8.2 MB
Details
- Authors
- Abstract
- lmmunotherapy is an alternative treatment modality for poor conditions associated with chemoresistanc e like refractory/relapsing primary B-precursor acute lymphoblastic leukaemia or minimal residual diseas e persistence. The immunotherapeutic effect of allogeneic stem cell transplantation is largely exploited in this context but graft-versus-host disease remains a major concern. Recently, improvements have been made in selectively engaging the immune system against the persistent disease. Blinatumomab is a dual binding antibody construct that redirects any T lymphocytes against B-precursor acute lymphoblastic leukaemia blasts. lt shows a very good activity in monotherapy in those poor risk conditions and is associated with a low toxicity profile suggesting this use earlier and in combination in the therapeutic course of B-precursor acute lymphoblastic leukaemia patients. ln this article, after a short overview of immunotherapeutic advances in B-precursor acute lymphoblastic leukaemia, the results of the main trials conducted with blinatumomab are discussed and put in perspective.
- Affiliations
Citations
Graux, C. (2017). Blinatumomab: beyond clinical trials. Belgian Journal of Hematology, 8(3), 107-112. https://hdl.handle.net/2078.5/178387 (Original work published 2017)